Cutaneous Rosai-Dorfman disease after Covid 19 vaccination treated with thalidomide

Dermatol Ther. 2022 Nov;35(11):e15864. doi: 10.1111/dth.15864. Epub 2022 Oct 7.

Authors

Marta Grimaldi¹, Francesca Perino², Gaia Moretta², Flaminia Antonelli¹, Andrea Paradisi¹, Francesca Ricci², Damiano Abeni², Biagio Didona², Luca Fania²

Affiliations

¹ U.O.C. Dermatologia, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Rome, Italy.
² IDI-IRCCS, Dermatological Research Hospital, Rome, Italy.

No abstract available

Publication types

Letter

MeSH terms

COVID-19 Vaccines / adverse effects
COVID-19*
Histiocytosis, Sinus* / diagnosis
Histiocytosis, Sinus* / drug therapy
Humans
Skin Diseases* / chemically induced
Skin Diseases* / drug therapy
Thalidomide / adverse effects
Vaccination

Substances

Thalidomide
COVID-19 Vaccines